![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14...
HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.4 | -2.05549845838 | 19.46 | 19.46 | 18.66 | 41947 | 18.94546684 | SP |
4 | -1.09 | -5.4094292804 | 20.15 | 20.71 | 18.66 | 35352 | 19.816925 | SP |
12 | -0.93 | -4.65232616308 | 19.99 | 20.71 | 18.66 | 30375 | 19.83427864 | SP |
26 | -0.93 | -4.65232616308 | 19.99 | 20.71 | 18.66 | 30375 | 19.83427864 | SP |
52 | -0.93 | -4.65232616308 | 19.99 | 20.71 | 18.66 | 30375 | 19.83427864 | SP |
156 | -0.93 | -4.65232616308 | 19.99 | 20.71 | 18.66 | 30375 | 19.83427864 | SP |
260 | -0.93 | -4.65232616308 | 19.99 | 20.71 | 18.66 | 30375 | 19.83427864 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions